IFN-α治疗白塞病葡萄膜炎的新进展

doi:10.3760/cma.j.issn.1674-845X.2016.07.016

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (4139 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Behcet disease (BD) is a chronic, recrudescent, systemic disease which involves multi-organ. Uveitis caused by BD is a common type of uveitis inducing blindness in China. There is no radical cure for this kind of uveitis at present. IFN-α is a kind of cytokine which has multiple biological effects. It has a dual immunomodulatory activity, and has been applied to uveitis patients with BD disease in recent years. Clinical investigation has found IFN-α treatment is effective in controlling the progress of BD uveitis, reducing the frequency of disease recurrence. For the BD uveitis patients who are resistance to normal steroids and immunosuppressive drugs, IFN-α treatment will bring new hope. Otherwise, the mechanism and long-term effect of IFN-α treatment need more clinical studies.

Key words： IFN-α Behcet′s disease Uveitis Progress of treatment

Corresponding Authors: Cai Li, Email: caili@fmmu.edu.cn

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Cai Li*
	Gao Wei
	Wang Yingwei
	Wang Yusheng

Cite this article:

Cai Li*,Gao Wei,Wang Yingwei等. Progress in IFN-α treatment of uveitis patients with Behcet′s disease[J]. Chinese Journal of Optometry Ophthalmology and Visual science, 2016, 18(7): 446-448.

URL:

https://www.cjoovs.com/EN/10.3760/cma.j.issn.1674-845X.2016.07.016 OR https://www.cjoovs.com/EN/Y2016/V18/I7/446

[1]	Mesquida M, Molins B, Llorenc V, et al. Current and future treatments for Behcet′s uveitis: road to remission[J]. Int Ophthalmol,2014,34(2):365-381. DOI:10.1007/s10792-013-9788-5.
[2]	Khairallah M, Accorinti M, Muccioli C, et al. Epidemiology of Behcet disease[J]. Ocul Immunol Inflamm,2012,20(5):324-335. DOI:10.3109/09273948.2012.723112.
[3]	Yang P, Fang W, Meng Q, et al. Clinical features of chinese patients with Behcet′s disease[J]. Ophthalmology,2008,115(2):312-318.e4. DOI:10.1016/j.ophtha.2007.04.056.
[4]	Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet′s disease: from East to West[J]. Clin Rheumatol,2010,29(8):823-833. DOI:10.1007/s10067-010-1430-6.
[5]	吴红华,李国华,陈华,等. 白塞病眼病111例临床分析[J]. 中华内科杂志,2014,53(1):44-47. DOI:10.3760/cma.j.issn.0578-1426. 2014.01.011.
[6]	Mendes D, Correia M, Barbedo M, et al. Behcet′s disease—a contemporary review[J]. J Autoimmun,2009,32(3-4):178-188. DOI:10.1016/j.jaut.2009.02.011.
[7]	Kitaichi N, Miyazaki A, Iwata D, et al. Ocular features of Behcet′s disease: an international collaborative study[J]. Br J Ophthalmol,2007,91(12):1579-1582. DOI:10.1136/bjo.2007.123554.
[8]	Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons (alpha/beta) in immunity and autoimmunity[J]. Annu Rev Immunol,2005,23:307-336. DOI:10.1146/annurev.immunol.23.021704.115843.
[9]	Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet′s disease: a comparative 4-week study[J]. Rheumatology (Oxford),2011,50(3):593-597. DOI:10.1093/rheumatology/keq366.
[10]	Yang DS, Taylor SR, Lightman SL. Interferon-alpha in the management of patients with Behcet′s disease[J]. Br J Hosp Med (Lond),2008,69(10):575-579. DOI:10.12968/hmed.2008.69.10.31317.
[11]	Saadoun D, Bodaghi B, Bienvenu B, et al. Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies[J]. Autoimmun Rev,2013,12(7):774-783. DOI:10.1016/j.autrev.2013.02.002.
[12]	Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease[J]. Surv Ophthalmol,2005,50(4):297-350. DOI: 10.1016/j.survophthal.2005.04.009.
[13]	Portales P, Reynes J, Pinet V, et al. Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo[J]. AIDS, 2003,17(4):495-504. DOI:10.1097/01.aids.00000 50816.06065.b1.
[14]	Deuter CM, Zierhut M, M?hle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behcet′s disease[J]. Arthritis Rheum,2010,62(9):2796-2805. DOI:10.1002/art.27581.
[15]	Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis[J]. Graefes Arch Clin Exp Ophthalmol,2006,244(12):1692-1695. DOI:10.1007/s00417-006-0346-y.
[16]	Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease[J]. Am J Ophthalmol,2008, 146(6):837-844.e1. DOI:10.1016/j.ajo.2008.08.038.
[17]	Deuter CM, Koetter I, Guenaydin I, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study[J]. Retina,2006,26(7):786-791. DOI:10.1097/01.iae.0000244265.75771.71.
[18]	Hatemi G, Silman A, Bang D, et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease[J]. Ann Rheum Dis,2009,68(10):1528-1534. DOI:10.1136/ard.2008.087957.
[19]	K?tter I, Günaydin I, Zierhut M, et al. The use of interferon alpha in Behcet disease: review of the literature[J]. Semin Arthritis Rheum,2004,33(5):320-335.
[20]	Liu X, Yang P, Wang C, et al. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet′s disease[J]. Rheumatology (Oxford),2011,50(2):293-298. DOI:10.1093/rheumatology/keq330.
[21]	Plskova J, Greiner K, Muckersie E, et al. Interferon-alpha: a key factor in autoimmune disease?[J]. Invest Ophthalmol Vis Sci,2006,47(9):3946-3950. DOI:10.1167/iovs.06-0058.
[22]	Warde N. Therapy: Behcet uveitis: good results for IFN-alpha-2a[J]. Nat Rev Rheumatol,2010,6(8):437. DOI:10.1038/nrrheum.2010.115.